Abstract

With five-year survival rates as low as 3%, lung cancer is the most common cause of cancer-related mortality worldwide. The severity of the disease at presentation is accredited to the lack of early detection capacities, resulting in the reliance on low-throughput diagnostic measures, such as tissue biopsy and imaging. Interest in the development and use of liquid biopsies has risen, due to non-invasive sample collection, and the depth of information it can provide on a disease. Small extracellular vesicles (sEVs) as viable liquid biopsies are of particular interest due to their potential as cancer biomarkers. To validate the use of sEVs as cancer biomarkers, we characterised cancer sEVs using miRNA sequencing analysis. We found that miRNA-3182 was highly enriched in sEVs derived from the blood of patients with invasive breast carcinoma and NSCLC. The enrichment of sEV miR-3182 was confirmed in oncogenic, transformed lung cells in comparison to isogenic, untransformed lung cells. Most importantly, miR-3182 can successfully distinguish early-stage NSCLC patients from those with benign lung conditions. Therefore, miR-3182 provides potential to be used for the detection of NSCLC in blood samples, which could result in earlier therapy and thus improved outcomes and survival for patients.

Authors	Visan, Kekoolani S; Lobb, Richard J; Wen, Shu Wen; Bedo, Justin; Lima, Luize G; Krumeich, Sophie; Palma, Carlos; Ferguson, Kaltin; Green, Ben; Niland, Colleen; Cloonan, Nicole; Simpson, Peter T; McCart Reed, Amy E; Everitt, Sarah J; MacManus, Michael P; Hartel, Gunter; Salomon, Carlos; Lakhani, Sunil R; Fielding, David; Möller, Andreas
Journal	Cancers
Pages
Volume	14
Date	1/01/2022
Grant ID
Funding Body
URL	http://www.ncbi.nlm.nih.gov/pubmed/?term=10.3390/cancers14010257